Generation and characterization of a tamoxifen-inducible lineage tracing tool

Yang Guo, Mengyan Zhu, Zhilan Yu, Qing Li, Yanjuan Chen, Lei Ci, Ruilin Sun, Ruling Shen

Abstract read

In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yang GuoModel Organism R&D Department, Shanghai Laboratory Animal Research Center, Shanghai, China.

Mengyan ZhuModel Organism R&D Department, Shanghai Laboratory Animal Research Center, Shanghai, China.

Zhilan YuModel Organism R&D Department, Shanghai Laboratory Animal Research Center, Shanghai, China.

Qing LiShanghai Engineering Research Center for Model Organizations, Shanghai Model Organisms Center, Inc., Shanghai, China.

Yanjuan ChenModel Organism R&D Department, Shanghai Laboratory Animal Research Center, Shanghai, China.

Lei CiShanghai Engineering Research Center for Model Organizations, Shanghai Model Organisms Center, Inc., Shanghai, China.

Ruilin SunShanghai Engineering Research Center for Model Organizations, Shanghai Model Organisms Center, Inc., Shanghai, China.

Ruling ShenModel Organism R&D Department, Shanghai Laboratory Animal Research Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The new targeted gene editing technologies, such as the CRISPR/Cas system, enable researchers to insert or delete genes at targeted loci efficiently. The Cre-loxp recombination system is widely used to activate or inactivate genes with high spatial and temporal specificity. Methods: Using the CRISPR/Cas9 system, we inserted the Results: After treatment with tamoxifen, the Discussion: This work supplied a new transgenic mouse as a valuable tool for lineage tracing in CD2-expressing cells, for conditional mutant studies of immune modulatory effects in a time-dependent manner, and analysis of the potential therapeutic effect of CD2-targeting biologics.

Indexed as

CD2 AntigensCell LineageGene Knock-In TechniquesIntegrasesTamoxifenAnimalsCRISPR-Cas SystemsGenes, ReporterMiceMice, TransgenicTransgenesCD2 AntigensCre recombinaseIntegrasesTamoxifenCD2conditional gene manipulationCreERT2/loxP systemtamoxifen-inducibletdTomato

Identifiers

PMID40129982

DOI10.3389/fimmu.2025.1482070

PMCPMC11931051

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.